PG11047: Phase Ia data

A dose-escalation, U.S. Phase Ia trial in 46 patients with advanced solid tumors established a MTD of 750 mg PG11047. Progen plans to use a 600 mg dose in an ongoing Phase Ib study of PG11047 in combi...